文献速递肾癌与肾肿瘤

转移性肾细胞癌原发肿瘤对系统治疗的应答:12项临床试验汇总分析

Response of Primary Renal Cell Carcinoma to Systemic Therapy.
PubMed 文献 · Eur Urol · 2019-10-06

该研究汇总分析了2003至2013年间12项II/III期临床试验中4736例转移性肾细胞癌患者,其中565例原发肿瘤未切除。一线系统治疗的原发肿瘤客观缓解率为19%,一线VEGF靶向治疗为28%,IMDC中危和低危患者分别为20%和9%。系统治疗可缩小原发肿瘤,支持对未行减瘤性肾切除术患者行系统治疗以缓解原发灶和转移灶。

要点

  • 一线VEGF靶向治疗原发肿瘤客观缓解率达28%。
  • IMDC中危患者原发肿瘤客观缓解率20%,低危9%。
  • 系统治疗可缩小原发肿瘤,支持其用于未行减瘤手术者。

核心结论

  • 系统治疗可缩小转移性肾细胞癌患者的原发肿瘤,VEGF靶向治疗应答率可达28%。

研究设计与样本

  • 汇总分析12项II/III期临床试验,纳入2003至2013年接受系统治疗的转移性肾细胞癌患者,共4736例,其中565例原发肿瘤未切除。

主要发现

  • 565例原发肿瘤未切除者中,461例(82%)为初治,283例(50%)接受一线VEGF靶向治疗,222例(39%)为IMDC低危。
  • 一线任何类型治疗的原发肿瘤客观缓解率为19%(95%CI 16-23)。
  • 一线VEGF靶向治疗的原发肿瘤客观缓解率为28%(95%CI 22-33)。
  • 任何线数VEGF靶向治疗的原发肿瘤客观缓解率为23%(95%CI 19-28)。
  • IMDC低危和中危患者的原发肿瘤客观缓解率分别为9%(95%CI 5-13)和20%(95%CI 15-27)。

临床怎么用

  • 对于转移性肾细胞癌未行 upfront 减瘤性肾切除术的患者,系统治疗可同时缓解原发肿瘤和转移灶。
  • 选择立即减瘤性肾切除术需仔细考虑患者和疾病特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upfront cytoreductive nephrectomy (CRN) in renal cell carcinoma (RCC) has come into question in recent prospective clinical trials. OBJECTIVE: We investigated the effect of systemic therapies on primary tumor response in patients with metastatic RCC. DESIGN, SETTING, AND PARTICIPANTS: A pooled analysis of 12 phase II/III clinical trials of metastatic RCC patients treated with systemic therapy between 2003 and 2013 was performed. Patients with one target lesion in the kidney and no prior nephrectomy were identified as having their primary tumor in place. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The objective response rate (ORR) of the primary tumor was defined as per the Response Evaluation Criteria in Solid Tumors (RECIST). ORR was assessed in the overall population and patient subsets based on prior treatment and International Metastatic RCC Database Consortium (IMDC) risk group. Cox's models adjusting for baseline characteristics, treatment, line of therapy, and site of metastases were used for survival analyses. RESULTS AND LIMITATIONS: In total, 4736 patients were identified, of whom 565 had their primary tumor in place: 461 (82%) were treatment naïve, 283 (50%) received first-line vascular endothelial growth factor (VEGF)-targeted therapy, and 222 (39%) were IMDC poor risk. The ORRs of the primary tumor were 19% (95% confidence interval 16-23) in patients treated with first-line therapy (any type), 28% (22-33) in those treated with first-line VEGF-targeted therapy, and 23% (19-28) in those treated with VEGF-targeted therapy (any line). The ORRs were 9% (5-13) and 20% (15-27) in IMDC poor- and intermediate-risk patients, respectively. CONCLUSIONS: Systemic therapy reduces primary tumor size in patients with metastatic RCC. Responses in primary tumors treated with VEGF-targeted therapy were observed in upward of 28% of patients. Selection of patients for immediate CRN requires careful consideration of patient and disease characteristics. PATIENT SUMMARY: Antiangiogenic therapy meaningfully decreases the size of primary kidney tumor. Hence, for patients with metastatic disease who are not undergoing upfront cytoreductive nephrectomy, systemic therapy can palliate both primary tumor and metastases.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bossé D, Lin X, Simantov R, et al. Response of Primary Renal Cell Carcinoma to Systemic Therapy. Eur Urol. 2019. PMID: 31594707. doi:10.1016/j.eururo.2019.08.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。